Sdi Share Discussion Threads

[buywell3] 05/6/2017 20:53

thanks PJ 1

So they only have an earnings growth of 20.8% on it but with some similar 2017 numbers

Against 45% this looks daft .... I just don't see why there is such a massive difference

who do we believe ? not that 20.8% earnings per share growth is bad , many companies would like it very much.

I wonder what SDI have planned on the tax credit side ?

the ft say this

Year on year Scientific Digital Imaging PLC grew revenues 21.83% from 6.96m to 8.47m while net income improved 1,197.73% from 44.00k to 571.00k.

my point is that the forecast numbers for 2017 turnover are £10.7M

this is a bigger growth %age wise yet the house broker has effectively downgraded the stock with their 20p repeat call

I don't understand why they would do this ??

in the last 18 months margins have also risen from 59% to over 63% latest interims

Revenue increased by 33% to £4,902,000
(2015: £3,671,000)
Profit before taxation for the period increased to
£410,000 (2015: £13,000)
Adjusted profit before taxation* for the period
increased to £446,000 (2015: £189,000)
Gross margin increased to 63.6% (2015: 58.0%)

[buywell3] 05/6/2017 20:16

I have just done them

£1.65M DIVIDED BY 88.8M shares is 1.858p

[martinthebrave] 05/6/2017 20:01

The numbers are supposedly Broker averages.

That said, 4Traders show the same f'casts for Rev & PBT but lower EPS @ 1.10 (2017) & 1.50 (2018).

Stockopedia have shares in circ @ 88.8m. the same Revs & Normalised EPS @ 1.70 & 1.90.

So, 4Traders lower EPS than the others.

I will look at the maths tomorrow!!

NB. Our posts crossed.

[buywell3] 05/6/2017 15:28

what are the 2017 forecast numbers on this anyone know ?

[genises] 02/6/2017 22:50

Onwards and upwards.
The seller is out!!

[rivaldo] 02/6/2017 13:27

Good news today (EDIT - bizarrely this appears to have brought out a few small sellers!):



"Friday 2nd June 2017

Leading German University opts for second Syngene imaging system

Cambridge, UK: Syngene, a world-leading manufacturer of image analysis solutions, today announced its G:BOX Chemi XX6 multi-application imager is being utilised by scientists at a top University in Germany to speed up analysis of genes and proteins associated with neurodegenerative conditions.

Researchers at the German University are using a G:BOX Chemi XX6 multi-application imager to rapidly detect genotypic changes on fluorescent DNA gels and accurately analyse proteins expressed in human cell lines and animal models of neurodegenerative diseases. To detect changes in protein expression, the scientists are utilising ECL-based chemiluminescent Western blots. This data is providing information which could help develop safer, more effective immunotherapies to treat incurable neurodegenerative conditions.

The Laboratory Manager at the German University stated: “We have had an older Syngene gel doc system in our lab for many years, which we use for visualising DNA on our genotyping gels. We are very happy with its performance but this system cannot analyse chemiluminescent Western blots. This meant we were spending many hours developing X-ray film of our Westerns and it was difficult, as well as time consuming trying to quantify protein amounts.”

The Laboratory Manager continued: “We upgraded to the newer G:BOX Chemi XX6 in 2016 because we like how quick and easy the Syngene imaging software is to use. The system is now being used daily by 10 researchers and we’re analysing our Western blot results much faster than when we were using X-ray film. The other benefits are that we have confidence in the protein quantification results we’re obtaining and we can store images which we can use directly in publications so we’re very happy with our G:BOX Chemi XX6 system.”

To find out about the exciting applications a G:BOX Chemi XX6 imager can perform, scientists can click this link: www.syngene.com/g-box-chemi-xx6/

“We’re proud to hear that this major German University has installed a second Syngene imaging system to accelerate their research in neurodegenerative diseases,” states Dr Martin Biggs, Sales Manager at Syngene. “Their choice of a G:BOX Chemi XX6 for use by so many different researchers demonstrates how robust and easy to use this technology is for producing accurate protein expression and genotyping results.”

[genises] 31/5/2017 10:49

Last bit gone through on my calculations
Onwards and very upwards.

[genises] 30/5/2017 19:56

Held up well over the last few months considering our seller has nearly sold the last of its 9%holding.
Nice buy at the end.!!

[johnv] 26/5/2017 15:50

Ok guys, puts my mind at rest

[pj 1] 26/5/2017 15:25

agree rivaldo

Management here are well aware of Market expectations, and the effect of not meeting such targets. Therefore in this case I'm extremely confident that they are one and the same.

[rivaldo] 26/5/2017 15:22

Management expectations should not usually be significantly different from market expectations if the company have done their job properly in guiding analysts - and SDI have usually done this well in the past.

If anything management expectations should be slightly higher than those in the market.

[pugugly] 26/5/2017 15:15

johnv - I am afraid I have to disagree with Hastings (whom I respect for his usual insight) - IMO the answer is often YES. Market expections are thosse of analysts - Management are internal.

[johnv] 26/5/2017 15:05

Wondering if " in line with management expectations" is different from " in line with market expectations"

[greenroom78] 26/5/2017 15:00

I agree with you all, but I tend to be fairly short term though unless I get a bit of headroom quickly between the price and my entry price. As that failed to materialise here I got defensive and moved on which is part of my current strategy. Best of luck to you all, I hope I can catch it again before it gets away from me.

[pj 1] 26/5/2017 14:51

hastings, LOL you beat me to it!!

Look forward to your updates, as always, from your meetings

[pj 1] 26/5/2017 14:50

There was an ''in-line'' trading statement a year ago at 11p

There was another ''in-line'' trading statement in December '16 at 16.5p

Today at 25p that is increases of 127% in 12 months and 51% in 6 months. Not bad going for ''in-line''.

Some 'Hot money'' arrived with the IC tip, no doubt some of that ''Hot money '' has left for the next tip today. I also suspect that SDI 's BoD were a little surprised by the spike up on that article. IMO they are a BoD who quietly go about their Business whilst ''doing what it says on the tin''. I half suspect the 'bland' nature is to defend against any more over enthusiasm.

[hastings] 26/5/2017 14:49

If it's any use SDI don't tend to say much other than at the results end, so personally not surprised by the little content today.I'm going to be speaking with and dropping by the company on results day, but for now all appears to be on track.

[shanklin] 26/5/2017 14:47

I presume the concern is that more acquisitions may imply more placings, which historically have been at a big discount to the prevailing share price.

[greenroom78] 26/5/2017 14:42

I sold first thing as an 'in-line' after a decent rise can attract short term selling, I had been considering it anyway as although there has been plenty of buying there is a clear overhang holding it back. I'm sure I'll be back but felt me limited funds could be better deployed elsewhere in the short term. No doubt there will be an acquisition pop up and I'll miss out, Sod's law and all that.

[garbetklb] 26/5/2017 14:32

I'm a bit puzzled by the reaction as the TS was pretty bland. I've bought a few more at 25.80 - not sure if to hold, or as short term....

[rivaldo] 26/5/2017 10:49

Evidently a few traders dropping out this morning - once again proving the folly of such manoeuvring, with the MMs taking full advantage and then the price bouncing nicely already.